Insider Selling: Organogenesis (NASDAQ:ORGO) Director Sells $63,827.90 in Stock

Organogenesis (NASDAQ:ORGO) Director Glenn Nussdorf sold 12,043 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $5.30, for a total value of $63,827.90. Following the sale, the director directly owned 2,953,548 shares of the company’s stock, valued at approximately $15,653,804.40. This represents a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Organogenesis Trading Down 4.3%

Shares of NASDAQ ORGO opened at $5.19 on Friday. The company has a quick ratio of 2.88, a current ratio of 3.32 and a debt-to-equity ratio of 0.01. Organogenesis has a 12 month low of $2.61 and a 12 month high of $7.08. The company has a market cap of $658.03 million, a price-to-earnings ratio of -43.21 and a beta of 1.68. The business has a fifty day simple moving average of $4.68 and a 200-day simple moving average of $4.30.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.11. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%.The firm had revenue of $150.86 million for the quarter, compared to analysts’ expectations of $134.10 million. Organogenesis has set its FY 2025 guidance at EPS. Sell-side analysts predict that Organogenesis will post -0.07 EPS for the current year.

Institutional Trading of Organogenesis

Several institutional investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC purchased a new stake in shares of Organogenesis during the second quarter worth about $24,804,000. Assenagon Asset Management S.A. raised its stake in Organogenesis by 748.1% during the second quarter. Assenagon Asset Management S.A. now owns 2,857,904 shares of the company’s stock valued at $10,460,000 after buying an additional 2,520,941 shares during the last quarter. Driehaus Capital Management LLC purchased a new position in shares of Organogenesis in the 1st quarter worth about $7,756,000. Invesco Ltd. raised its holdings in Organogenesis by 779.7% in the first quarter. Invesco Ltd. now owns 1,069,252 shares of the company’s stock worth $4,619,000 after buying an additional 947,705 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Organogenesis by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company’s stock valued at $19,144,000 after acquiring an additional 841,618 shares in the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ORGO. Wall Street Zen upgraded Organogenesis from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Organogenesis in a research note on Tuesday. Cantor Fitzgerald raised their price target on Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a report on Friday, August 8th. Finally, BTIG Research raised their price objective on shares of Organogenesis from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, November 20th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.00.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.